NASDAQ · Biotechnology

Karyopharm Therapeutics Inc. (KPTI) Stock

$0.61 +0.83% NASDAQ: KPTI Healthcare

Valuation

MetricValue
Price$0.61
Market Cap$13.71M
P/E Ratio-0.03
P/B Ratio-0.06
P/S Ratio0.10
EPS (TTM)$-17.93
52-Week High$10.99
52-Week Low$0.60
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE77.63%
ROA-201.89%
ROCE359.36%
Gross Margin-62.33%
Operating Margin-62.33%
Net Margin-153.28%
Debt/Equity-0.65
Current Ratio1.12

Annual Financials (USD)

Metric20212022202320242025
Revenue$210.0M$157.0M$146.0M$145.0M$146.0M
Operating Profit$-98.0M$-142.0M$-130.0M$-119.0M$-91.0M
Net Profit$-124.0M$-165.0M$-143.0M$-76.0M$-196.0M
EPS$-24.75$-30.28$-18.79$-9.41$-17.93
Op Margin-46.8%-90.5%-88.7%-82.2%-62.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$305.0M$358.0M$240.0M$164.0M$108.0M
Total Liabilities$385.0M$375.0M$377.0M$350.0M$401.0M
Cash$190.0M$135.0M$52.0M$62.0M$61.0M
Borrowings$181.0M$179.0M$177.0M$195.0M$234.0M

Latest News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire · Jul 1, 2026 Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update Simply Wall St. · Jun 25, 2026 Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress PR Newswire · Jun 14, 2026 Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress GlobeNewswire · Jun 14, 2026 How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI) Simply Wall St. · Jun 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-107.0M$-150.0M$-93.0M$-127.0M$-75.0M
Investing Cash Flow$136.0M$-104.0M$8.0M$95.0M$43.0M
Financing Cash Flow$4.0M$4.0M$0$-43.0M$0
Net Cash Flow$108.0M$-61.0M$-84.0M$10.0M$-2.0M
Free Cash Flow$-113.0M$-150.0M$-93.0M$-128.0M$-75.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-1.00
FCF Yield-447.04%
Quick Ratio0.76
Interest Coverage-1.67
Return 1Y109.85%
Return 3Y-57.22%
Return 5Y-92.74%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGSAligos Therapeutics, Inc. $5.34 +0.56% -0.76 $33.05M 0.00%
BRNSBarinthus Biotherapeutics plc $0.67 +4.69% -0.41 — 0.00%
CVMCel-Sci Corporation $1.94 -0.51% -0.90 $13.33M 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%
INMBINmune Bio Inc. $1.89 +3.28% -2.81 $50.25M 0.00%

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is led by CEO Richard A. Paulson, employs 279 people, headquartered in US, publicly traded since 2013.

Karyopharm Therapeutics Inc. (KPTI) stock trades at $0.61 with a market capitalization of $13.71M. The stock is valued at a price-to-earnings (P/E) ratio of -0.03, price-to-book of -0.06, price-to-sales of 0.10. Over the past 52 weeks the stock has ranged between $0.60 and $10.99, and currently trades 94.4% below its 52-week high.

On profitability, Karyopharm Therapeutics Inc. generates a return on equity (ROE) of 77.63% — well above the market average, a sign of a high-quality business, return on capital employed of 359.36%, an operating margin of -62.33%, a net profit margin of -153.28%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides